Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Blepharitis Overview 6 Therapeutics Development 7 Pipeline Products for Blepharitis - Overview 7 Blepharitis - Therapeutics under Development by Companies 8 Blepharitis - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Blepharitis - Products under Development by Companies 12 Blepharitis - Companies Involved in Therapeutics Development 13 Allergan Plc 13 InSite Vision Incorporated 14 Kala Pharmaceuticals, Inc. 15 NicOx S.A. 16 Quorum Innovations LLC 17 Senju Pharmaceutical Co., Ltd. 18 Blepharitis - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 AGN-195263 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 azithromycin - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 azithromycin - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 dexamethasone acetate - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 fluticasone propionate - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 ISV-405 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 loteprednol etabonate - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Qi-305 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Blepharitis - Dormant Projects 40 Blepharitis - Product Development Milestones 41 Featured News & Press Releases 41 Jul 08, 2014: InSite Vision Plans to Submit New Drug Application to FDA for DexaSite for the Treatment of Blepharitis in Adults 41 Nov 12, 2013: Kala Pharmaceuticals Presents Preclinical Data on Mucus Penetrating Particles at 2013 AAPS Annual Meeting and Exposition 41 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 43 Disclaimer 44

List of Tables Number of Products under Development for Blepharitis, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Comparative Analysis by Early Stage Development, H2 2016 11 Products under Development by Companies, H2 2016 12 Blepharitis - Pipeline by Allergan Plc, H2 2016 13 Blepharitis - Pipeline by InSite Vision Incorporated, H2 2016 14 Blepharitis - Pipeline by Kala Pharmaceuticals, Inc., H2 2016 15 Blepharitis - Pipeline by NicOx S.A., H2 2016 16 Blepharitis - Pipeline by Quorum Innovations LLC, H2 2016 17 Blepharitis - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016 18 Assessment by Monotherapy Products, H2 2016 19 Number of Products by Stage and Target, H2 2016 21 Number of Products by Stage and Mechanism of Action, H2 2016 23 Number of Products by Stage and Route of Administration, H2 2016 25 Number of Products by Stage and Molecule Type, H2 2016 27 Blepharitis - Dormant Projects, H2 2016 40 List of Figures Number of Products under Development for Blepharitis, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Clinical Stage Development, H2 2016 10 Assessment by Monotherapy Products, H2 2016 19 Number of Products by Targets, H2 2016 20 Number of Products by Stage and Targets, H2 2016 20 Number of Products by Mechanism of Actions, H2 2016 22 Number of Products by Stage and Mechanism of Actions, H2 2016 22 Number of Products by Routes of Administration, H2 2016 24 Number of Products by Stage and Routes of Administration, H2 2016 24 Number of Products by Molecule Types, H2 2016 26 Number of Products by Stage and Molecule Types, H2 2016 26

Allergan Plc InSite Vision Incorporated Kala Pharmaceuticals, Inc. NicOx S.A. Quorum Innovations LLC Senju Pharmaceutical Co., Ltd.